



---

## FOR IMMEDIATE RELEASE

### **Lee's Pharmaceutical Appoints Dr. Giuseppe Bianchi to as Chief Scientific Officer**

Hong Kong, China (October 12, 2012) – Lee's Pharmaceutical Holdings Limited ("Lee's") today announced that Dr. Giuseppe Bianchi has joined the Company as Chief Scientific Officer Lee's and CVie Therapeutics Company Limited ("CVie").

Prof. Bianchi's research focuses is cardiovascular and renal pathology and pharmacology using genetic approaches. In collaboration with a large group of experts both in Milan and abroad, he has studied both patients and animal models with a variety of disciplines (clinical medicine, pathophysiology, epidemiology, cellular and molecular biology and genetics). These studies have led to the identification of two molecular mechanisms: the polymorphism of adducin genes and endogenous ouabain that were used as targets for the development of novel therapeutic agents. Two compounds have been selected and are now in phase II clinical trials for the therapy of hypertension and heart failure, respectively

"It is a great honor to have Dr. Bianchi serves as Chief Scientific Officer of CVie Therapeutics, said Dr. Benjamin Li, the Chief Executive Officer of Lee's Pharmaceutical Holdings Ltd, "As inventor of both drugs Rostafuroxin and Istaroxime, Dr. Bianchi has devoted most of his professional life in understanding the underling genetic triggering mechanism of hypertension. With his knowledge and understanding, it will be instrumental to the success of these two projects."

Giuseppe Bianchi, MD, PhD pharmacology, Hon. MD Universities of Berlin and Upsala, is Hon. member of the Alpha Omega Alpha Medical Society CA U.S.A., Italian societies of hypertension, U.S.A. National Kidney Foundation and other scientific organizations. He is also Professor Emeritus at the "Vita Salute" S. Raffaele University, and Scientific Director of the Prassis Sigma-Tau cardiovascular research institute.

He is present and past member of the Editorial Boards of 12 international journals and invited speaker or chairman at more than 500 national and international meetings. He has published more than 300 articles in peer-review journals including high impact journals such as Nature, Science Trans. Med., New England Journal of Medicine and Lancet and more than 200 chapters or reviews in books. Over the years, Prof. Bianchi has combined his academic and clinical experience with parallel work in collaboration with pharmaceutical companies



(Lepetit S.p.A., Farmitalia Carlo Erba, and Sigma-Tau S.p.A.) in order to develop a targeted therapeutic approach to cardiovascular diseases through laboratory and in clinical practice.

#### **About Lee's Pharmaceutical**

Lee's Pharmaceutical Holdings Limited ("Lee's") is a research-based Hong Kong biopharmaceutical company with over 18 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with 20 international companies and currently has 13 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. For further information about Lee's Pharmaceutical: Website: [www.leespharm.com](http://www.leespharm.com)

#### **About CVie**

CVie is a joint venture between Lee's Pharmaceutical Holdings Ltd. and a reputable US venture capital and is a stand along drug development company specialized in cardiovascular diseases. CVie owns two phase II assets that target cardiovascular disease with significant unmet medical need. In its first day of operation, CVie has successfully filed to the SFDA the application for a global Phase IIb clinical study (Protocol No. CVT-CT-1207-001) in China for one of its portfolio products Rostafuroxin. The study aims to using pharmacogenomic approach to evaluate the antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan®, assessed by office and ambulatory blood pressure monitoring in a hypertensive population. It is expected to initiate the clinical trial respectively in Italy at Q4 2012 and in China at Q3 2013.

#### **Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.*



*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*